4 results about "Staphylococcal infections" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

This disclosure provides a method reducing the number of Staphylococcus aureus bacterial cells in a subject and a method of treating or preventing diseases or disorders caused by S. aureus. This disclosure also provides a method of diagnosis or prognosis of a disease or disorder caused by S. aureus.

The present invention belongs to the fields of infectious microbial diseases and medicines. Provided is the use of compound 5928-0054 in the preparation of a drug against Staphylococcus aureus hemolysin. It is found that compound 5928-0054 can neutralize the toxicity of Staphylococcus aureus hemolysin, exhibits a protective effect on mice infected with MRSA Staphylococcus aureus USA300, and can be used in the preparation of a drug against Staphylococcus aureus hemolysin and a drug for preventing or treating Staphylococcus aureus infections. Compound 5928-0054 is found to have a new pharmaceutical value, i.e. providing a new drug for the prevention and treatment of Staphylococcus aureus infections. Compound 5928-0054 can neutralize hemolysin, the major virulence factor of Staphylococcus aureus, thereby alleviating inflammatory injuries.